BO25430

AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.
  • Open at Saint-Cloud since : 22/12/2023
  • Target : Adult
  • Phase : Clinical trial

Trial description

The main objectives of this study are as follows:;- Provide trastuzumab emtansine treatment as monotherapy or in combination with other therapeutic agents in patients with HER2-positive metastatic cancer already benefiting from trastuzumab emtansine treatment in other trials promoted by Roche/Genentech that we calls ÀparentÀ tests.;- Ensure continuity of treatment in patients in the control arm of study BO21976/TDM4450g who benefited from the treatment administered during the study.;Patients in the control arm of study BO21976/TDM4450g who discontinued treatment due to disease progression may be eligible to receive treatment with trastuzumab emtansine;- Collect safety and tolerability data relating to the long-term administration of trastuzumab emtansine treatment as monotherapy or in combination with other therapeutic agents.

Main investigator